Find a Research Study

To evaluate the impact of non-Newtonian behavior on hemodynamic efficiency in children and young adults who have undergone the Fontan procedure.

Food Choices in patients with Type 2 Diabetes.

We are studying the role of gut microbiome diversity on the mucosal and systemic responses to Ty21a vaccine. This is to determine if a given microbiota composition is associated with specific immune responses and to evaluate the impact of an oral typhoid vaccination on the human gut microbiota.

The purpose of this study is to see how young athletes perform sport tasks and to see what movement patterns are related to future injury risk.

To investigate the connection between diet, genetics, and diseases in Hispanic / Latino youth.

To improve patient care and achieve the best health outcomes possible for children with IBD.

The purpose of the study is to collect information from children 0-18 years of age with all types of pancreatitis to determine the number of children diagnosed with this condition, understand the causes and progression of the disease, and review laboratory and imaging findings as well as responses to any treatments given.

5,000 transgender women are testing a LifeSkills Mobile intervention web-app to see if it helps reduce condomless sex, increase PrEP use, and decrease HIV infections over several years.

Data Collection only. By reviewing the charts of CAH infants who come to our facility for treatment, we hope to discover which treatments, all of which are standard of care, lead to better outcomes for patients (primarily in the first year of life).

This is a Phase 3, randomized, double-blind, placebo-controlled study to evaluate the efficacy, safety, and tolerability of crinecerfont versus placebo administered twice daily (bid) with breakfast and evening meals for28 weeks in approximately 81 pediatric subjects with classic congenital adrenal hyperplasia (CAH) due to21-hydroxylase deficiency. Eligible subjects will be randomly assigned in a 2:1 ratio (active:placebo) to either crinecerfont (25 mg bid via oral solution for subjects 10 to <20 kg, 50 mg bid via oral solution for subjects 20 to <55 kg, or 100 mg bid via oral capsules for subjects ≥55 kg) or matching placebo (oral solution placebo for subjects <55 kg and oral capsule placebo for subjects ≥55 kg). Dose assignment from Day 1 to Week 28 will be based on the subject’s weight at Day 1. After the 28-week placebo-controlled treatment period, there will be a 24-week, open-label treatment period, during which all subjects will receive crinecerfont at doses based on their Week 28 body weight.